The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Moreover, high-efficacy monoclonal antibody therapy -- ocrelizumab (Ocrevus), rituximab (Rituxan), or natalizumab (Tysabri) - ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

However, she reckons it will still trail Roche's first-to-market anti-CD20 drug Ocrevus (ocrelizumab), even though that drug needs to be administered by intravenous infusion. While it requires a ...

Roche’s top-performing asset was the multiple sclerosis drug Ocrevus; sales increased 11% to 1.69 billion Swiss francs. Sales of Vabysmo, an age-related macular degeneration (AMD) treatment ...

Roche’s top-performing asset was the multiple sclerosis drug Ocrevus; sales increased 11% to 1.69 billion Swiss francs. Sales of Vabysmo, an age-related macular degeneration (AMD) treatment ...

Progressive Multifocal Leukoencephalopathy (PML) is a severe, life-threatening condition that poses a particular risk for MS ...

With a rising of cost-of-living, more people are moving into remote Australia for cheaper housing. In a rising cost-of-living crisis, housing affordability and lifestyle factors are increasingly ...

‘A TOADY’: Lau, a Chinese political advisory body member, sparked controversy with his song “Chinese People” and the concert was said to be part of China’s “united front” tactics Employment ...